ライフサイエンスコーパス: joint pain

1 depression, smoking, alcohol use, and other joint pain).

2 with objective measures of skin clearance or joint pain.

3 enes for the management of temporomandibular joint pain.

4 emoved from the study because of intolerable joint pain.

5 s can be altered significantly by changes in joint pain.

6 in elasticity, tissue fragility, and chronic joint pain.

7 p emphasizing nonpharmacologic management of joint pain.

8 gue without exacerbating disease activity or joint pain.

9 recommended for aromatase inhibitor-related joint pain.

10 zation into broader treatment guidelines for joint pain.

11 d vomiting, abdominal pain, muscle pain, and joint pain.

12 ation, subchondral bone plate sclerosis, and joint pain.

13 The hallmark symptom of OA is joint pain.

14 erized by an acute febrile phase and chronic joint pain.

15 tes robust oral activity in rodent models of joint pain.

16 made between subjects with and those without joint pain.

17 al and central sensitization contributing to joint pain.

18 ritis are accompanied by significant chronic joint pain.

19 cules that mediate osteoarthritis-associated joint pain.

20 ature about obesity, knee osteoarthritis and joint pain.

21 f articular cartilage accompanied by chronic joint pain.

22 0.74-0.81) for the 267 participants with no joint pain.

23 P-13 inhibitors on cartilage degradation and joint pain.

24 subjectively better control of the rash and joint pain.

25 t pathology and attenuation of the attendant joint pain.

26 the 300 participants with 2 or more sites of joint pain, 0.90 (95% CI, 0.87-0.92) for the 181 partici

27 tibody (2 points), and absence of peripheral joint pain (1 point).

28 Difference in change in joint pain (11-point numeric rating scale, with 0 indica

29 39% (23-57), and 86% (56-93), respectively; joint pain 14% (11-18), 42% (26-60), and not available,

30 The most frequent adverse events were joint pain (15 [38%]), muscle cramp (15 [38%]), and fati

31 d fatigue (14 [38%]), nausea (16 [43%]), and joint pain (17 [46%]) in the 40 mug group.

32 diagnosis in patients in the community were joint pain (2.5%), anxiety (1.2%), and prescriptions for

33 hospital were venous thromboembolism (3.5%), joint pain (2.7%), and breathlessness (2.8%).

34 ed moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and att

35 %), dermatitis (25.3%), oral ulcers (24.2%), joint pain (23.0%), pleural effusion (16.5%) and increas

36 e seronegative population; P<.001), bone and joint pain (27% vs. 9%; P<.001), headache (27% vs. 12.3%

37 41 (5%) had fatigue, 41 (5%) had muscle and joint pains, 37 (5%) had nausea, 36 (4%) had vomiting, 3

38 [corrected] [13%] vs 85 [corrected] [12%]), joint pain (41 [corrected] [6%] vs 38 [5%]), infection (

39 s. 10.1%), memory loss (29.2% vs. 4.8%), and joint pain (47.5% vs. 17.5%).

40 ), joint stiffness (64/243 patients [26.3%]) joint pain (62/243 patients [25.5%]), muscle weakness (6

41 gue (74%; grades 2 and 3 in 19% and 2%), and joint pain (63%; grades 2 and 3 in 19% and 0%).

42 llows: pruritus (95 %), skin burning (81 %), joint pain (69%), arthritis (51%), and psoriatic arthrit

43 loss of appetite (87.0%), headache (77.9%), joint pain (73.7%), vomiting (71.2%), and diarrhea (70.6

44 63.0 vs. 65.5), myalgia (98.0 vs. 74.0), and joint pain (93.5 vs. 107.5) was not significantly differ

45 ycycline did not reduce the mean severity of joint pain, although pain scores in both treatment group

46 survey, 94 (47%) reported having AI-related joint pain and 88 (44%) reported AI-related joint stiffn

47 during inflammatory arthritis and results in joint pain and bone malformations.

48 ation between ARTN, and clinical measures of joint pain and disability.

49 measures (PROMs) used to monitor changes in joint pain and function following percutaneous treatment

50 led that NGF inhibitors substantially reduce joint pain and improve function compared with NSAIDs for

51 matic resolution of tophi, decreased chronic joint pain and improved quality of life.

52 tanezumab was associated with a reduction in joint pain and improvement in function, with mild and mo

53 When relevant, evolution of joint pain and nail involvement was reported.

54 er musculoskeletal disorders, which includes joint pain and osteoporosis ($108.6 billion [95% CI, $10

55 th the clinical course of psoriasis, whereas joint pain and peripheral enthesitis may indicate the pr

56 Joint pain and poor functional status were the most comm

57 Relieving joint pain and preventing its recurrence are primary aim

58 or acute neuroborreliosis more often now had joint pain and sleep difficulty and lower scores on the

59 ikely than other patients to have AI-related joint pain and stiffness (odds ratio [OR] = 4.08, 95% CI

60 eated with TA had significant improvement of joint pain and stiffness, which was not seen with SA.

61 rmone-sensitive breast cancer, but can cause joint pain and stiffness.

62 on adverse events were a short-term flare in joint pain and swelling following treatment, a side effe

63 Characterized by acute fever with joint pain and swelling, most patients recover from this

64 oman, was seen with urticaria and associated joint pain and swelling.

65 nal study to describe the characteristics of joint pain and to examine the relationship between QST m

66 ivity measures (daily diary reports of rash, joint pain and/or swelling, and fevers), health quality

67 tective effects and can potentially modulate joint pain, and are, therefore, uniquely suited as poten

68 h CHIKV results in the development of fever, joint pain, and arthralgia that can become chronic and l

69 presentations such as severe back and small joint pain, and debilitating arthritis associated with c

70 ads to deterioration of articular cartilage, joint pain, and decreased quality of life.

71 ue, nausea, liver pain, anorexia, muscle and joint pain, and general health remained significantly be

72 -dose group (two feverish, two headache, one joint pain, and one muscle pain).

73 sociated with severity of pruritus, burning, joint pain, and psoriatic arthritis.

74 ge, increasing fat mass (in kilograms), knee joint pain, and reduced quadriceps strength.

75 age, fibromyalgia, apophyseal and sacroiliac joint pain, and sacral insufficiency fractures.

76 hich is associated with cold-induced fevers, joint pain, and systemic inflammation.

77 Overall, fever, joint pain, and/or night sweats were reported in 27 (47%

78 severe form of HFMD associated with fevers, joint pains, and widespread painful eruptions.

79 lationship between occupational hand use and joint pain; and the extent of occupational hand use amon

80 d factor, and symptoms, such as inflammatory joint pain, are at high risk of developing rheumatoid ar

81 with inflammatory joint pain in female mice, joint pain associated with osteoarthritis in male mice,

82 male mice, as well as both knee swelling and joint pain associated with repeated intra-articular inje

83 Patient-reported flare, joint pain at rest, warm joints, and swollen joints were

84 tients with diagnoses of limb, extremity, or joint pain, back pain, and neck pain for each week, patt

85 tion, it is essential that the management of joint pain be considered in light of the impact of multi

86 h OA also bore elevated joint diameters with joint pain behavior measured as decreased the stride len

87 e II collagen (UCII) on the inflammation and joint pain behavior of rats with osteoarthritis (OA).

88 ults (aged >=18 years) with ACPA positivity, joint pain (but no swelling), and signs of osteitis, syn

89 s the duration and severity of abdominal and joint pain, but corticosteroids do not prevent the devel

90 rted more chronic headaches or migraines and joint pain, but experienced similar levels of other type

91 s of education on walking knee pain, overall joint pain (by HAQ), and general health status (by QWB)

92 health; chronic abdominal, pelvic, back, and joint pain; chronic headaches or migraines; obesity; ast

93 AIMSS with duloxetine would improve average joint pain compared with placebo.

94 ronic autoimmune condition, characterised by joint pain, damage and disability, which can be addresse

95 ative joint disease which causes substantial joint pain, deformity and loss of activities of daily li

96 Dry skin, fatigue, itching, and bone/joint pain each were reported by > or =50% of patients.

97 ), osteoarthritis (7.1 million), nonspecific joint pain/effusion (7.0 million), and rheumatoid arthri

98 injection, one patient experienced moderate joint pain exacerbation that resolved spontaneously.

99 and a syndrome comprising diffuse muscle and joint pain, fever, lethargy and anorexia.

100 , chills (12 [23%]), muscle ache (19 [36%]), joint pain (five [9%]), and nausea (four [8%]), the freq

101 jection of Nano-PAZII can effectively reduce joint pain for a prolonged time without substantial side

102 e viral disease that causes fever and severe joint pain for which there is no direct acting drug trea

103 omplex disease of cartilage characterised by joint pain, functional limitation, and reduced quality o

104 revalent joint disease and a common cause of joint pain, functional loss, and disability.

105 valent joint disease and a frequent cause of joint pain, functional loss, and disability.

106 ng in appropriate sites and other causes for joint pain have been excluded.

107 rted by 61.0% of survivors, with pairings of joint pain, headache, or fatigue the most frequent.

108 orted by 61.0% of survivors with pairings of joint pain, headache, or fatigue the most frequent.

109 orted higher rates of physical symptoms (eg, joint pains, headaches, and hot flashes) than healthy wo

110 ent degenerative joint disease, resulting in joint pain, impaired movement, and structural changes.

111 All investigated symptoms except joint pain improved after diagnosis and initiated gluten

112 te clearance of skin lesions associated with joint pain improvement.

113 A (cOA) was defined as an overlap of rOA and joint pain in >= 1 joint.

114 administration of GW3965 potently alleviated joint pain in a rat meniscal tear model of osteoarthriti

115 ) had more joint pain (odds ratio for having joint pain in any joint, 2.1 [CI, 1.2 to 3.5]; P = 0.007

116 ll-cell interactions that drive inflammatory joint pain in both mice and humans.

117 l sensitization associated with inflammatory joint pain in female mice, joint pain associated with os

118 that causes acute febrile illness and severe joint pain in humans.

119 ine ameliorate inflammation in cartilage and joint pain in OA mice, offering a potential therapeutic

120 Joint pain in older adults is a problem commonly present

121 s of brief, simple assessment and staging of joint pain in older adults.

122 Although joint pain in rheumatoid arthritis (RA) is conventionall

123 described and discussed their experience of joint pain in the context of standard self-assessment qu

124 r three months before admission, followed by joint pains in her knees, elbows and several proximal in

125 hree of eight patients treated at 175 mg/m2 (joint pains in two, skin in one).

126 tments often overlook symptoms like back and joint pain, increasing burden.

127 ated by PSAM(4)-GlyR activation in acute and joint pain inflammation mouse models.

128 Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Un

129 Further study of therapy-induced joint pain is necessary.

130 been presumed that rheumatoid arthritis (RA) joint pain is related to inflammation in the synovium; h

131 Similar patterns were observed for worst joint pain, joint stiffness, pain interference, and func

132 ded injection-site AEs from days 1 to 5, and joint pain, joint swelling, vesicular lesions (blisters)

133 interest of Latinos in various arthritis and joint pain management programs could prove to be an impo

134 lower adjusted risks for all symptoms except joint pain ME/CFS-related symptoms.

135 ficacious in the acute model and the chronic joint pain model.

136 s had cOA, depending on the cut-off value of joint pain; moderate (2), or mild (1), respectively.

137 Symptoms of headache, fatigue, joint pain, muscle pain, hearing loss, visual loss, numb

138 erized by gastrointestinal symptoms, chills, joint pain, myalgia, thrombocytopenia, leukocytopenia, a

139 with American Indians who experience chronic joint pain (n = 56), to elicit descriptions and self-rep

140 dverse effects were dryness (n = 44; 80.0%), joint pain (n = 8; 14.5%), and eczema (n = 5; 9.1%).

141 Joint pain occurred in 84 of 129 patients (65%) with dox

142 ion to study evaluation, 6.0 years) had more joint pain (odds ratio for having joint pain in any join

143 on of the foot or ankle, and 14.9% had ankle joint pain on most days in the past 4 weeks.

144 o > 4 weeks of reduced exercise, hand/finger joint pain on most days of the last month, self-reported

145 mined by a rheumatologist because of chronic joint pain or evidence of small-vessel disease (0.7%).

146 and autoimmune diseases, are accompanied by joint pain or inflammation, often mediated by circulatin

147 ophageal reflux disease, malaise or fatigue, joint pain or myalgias, constipation, insomnia, polyuria

148 ophageal reflux disease, malaise or fatigue, joint pain or myalgias, polyuria, weakness, abdominal pa

149 nt or physician assessment), joint swelling, joint pain or tenderness, erythrocyte sedimentation rate

150 ly mild or moderate and short-lived, such as joint pain or upper respiratory symptoms.

151 (OR 1.27; 95% CI 0.08, 19.63) or prevent new joint pains (OR 0.72; 95% CI 0.11, 4.68) in RA participa

152 n EM was present, during initial episodes of joint pain, or during the maximal period of arthritis.

153 nistration regimen, injection-site reaction, joint pain, out-of-pocket cost, and a no-additional trea

154 ith 37 of 304 patients (12%) without initial joint pain (P < .001).

155 mmatory marker associated with lower odds of joint pain (p=0.04).

156 ere in the body influences the experience of joint pain, pain is inextricable from function, and adap

157 mbolization is a rapidly growing therapy for joint pain, particularly in cases where conservative mea

158 the clinical disconnect in which symptomatic joint pain patients present without radiographic evidenc

159 However, in some patients, joint pain persists, lasting for months or even years.

160 ting illness in 7-10 days, with cessation of joint pain post-acute episode.

161 at emphasized nonpharmacologic management of joint pain, preservation of function by problem-solving,

162 characterised by fever, headache, muscle and joint pains, rash, nausea, and vomiting.

163 omized clinical trial, women with AI-related joint pain receiving 12 weeks of TA had reduced pain at

164 n or pharmacological blockade, in persistent joint pain reduced fast-onset sensory, functional and ac

165 novium, as well as a significant increase in joint pain-related behaviors.

166 -associated disease characterized by chronic joint pain resulting from degradation of articular carti

167 tional medicinal applications like useful in joint pain, rheumatoid arthritis, inflammation, digestiv

168 isted after adjustment for CVD risk factors, joint pain, rheumatoid factor positivity, and inflammato

169 arly-stage breast cancer and who had average joint pain score of >/= 4 out of 10 that developed or wo

170 By 12 weeks, the average joint pain score was 0.82 points lower for patients who

171 the Short Form 36 (SF-36) and self-reported joint pain scores at baseline and after 1 year.

172 Worst joint pain scores decreased by 1.6 points (29%) at 12 mo

173 se in recent injuries and in upper and lower joint pain scores post-programme.

174 Nonsignificant improvements in joint pain scores were seen with PHT use (odds ratio [OR

175 Joint pain (sensitivity, 85%; 95% confidence interval [C

176 st pain, fatigue, headache, fever, muscle or joint pain, shortness of breath) were the most important

177 n routine clinical settings and across other joint pain sites, our findings suggest that focal charac

178 reast cancer receiving an AI who had a worst joint pain/stiffness score >/= 5 of 10 using the Brief P

179 ly mitigated disease severity as measured by joint pain, structural damage, and systemic and local in

180 Data on overall joint pain, swelling and stiffness, and activities of da

181 Joint pain, swelling, and stiffness can endure for month

182 n, elbow, knee and metacarpophalangeal (MCP) joint pain, swelling, and/or deformity, and radiographic

183 codes 715, 716, or 719, and if they reported joint pain, swelling, or stiffness during the previous 1

184 typically induced by cold (rash, fever, and joint pain/swelling) improved within days of rilonacept

185 rns and calluses, fungal signs, edema, ankle joint pain, tenderness to palpation, and sensory loss.

186 Treatment response was based on joint pain/ tenderness and swelling scores and physician

187 efinition of treatment response was based on joint pain/tenderness and swelling scores and physician

188 n in patients with axial manifestations, and joint pain/tenderness scores and joint swelling scores i

189 ional hand use were more likely to have hand joint pain than those with moderate hand use (66% versus

190 g disease in humans characterized by intense joint pain that can persist for weeks, months, or even y

191 d to acute febrile illness with debilitating joint pain that may persist as chronic arthritis.

192 fected with CHIKV suffer from incapacitating joint pain that severely affects their daily functioning

193 ong-term painful and debilitating muscle and joint pain, the pathogenesis of which remains unknown.

194 a rapid onset of high fever and debilitating joint pain, though in practice, etiologic confirmation o

195 The primary end point was average joint pain through 12 weeks, examined using multivariabl

196 ain across a diverse set of conditions, from joint pain to bone pain, chemotherapy-induced neuropathi

197 e inflammation, experts most often attribute joint pain to central nervous system dysfunction.

198 yndromes (ie, fatigue, sleep quality, muscle/joint pains, unrefreshing sleep, and dizziness/fainting,

199 ed to calculate 3-dimensional moments at the joints; pain, using a separate visual analog scale for e

200 An increase in bone or joint pain was more pronounced, particularly in the shor

201 Joint pain was not generally assumed to be arthritis nor

202 Although a relationship between ARTN and joint pain was not ruled out.

203 Severity of joint pain was recorded at 6-month intervals.

204 Joint pain was reported by 10% of subjects recently HIV

205 ACPA and rheumatoid factor with inflammatory joint pain were recruited.

206 s in fatigue were correlated with decreasing joint pain, whereas improvements in symptoms of depressi

207 phavirus, causes febrile disease, muscle and joint pain, which can become chronic in some individuals

208 Therapeutic modulation of chronic facet joint pain with the use of various pharmacologic agents

209 use body pain including headache, muscle and joint pain with their military counterparts without GWI

210 tal of 66.2% of the subjects reported recent joint pain, with a median average pain severity of 5 of

211 p. mosquitoes-causing fever and debilitating joint pain, with frequent long-term health implications

212 nd 219 healthy controls and individuals with joint pain without an underlying inflammatory cause.

213 ddition, she had an 8-month small and medium joint pain, without edema or erythema.